ZEVRA THERAPEUTICS INC (ZVRA)
Health Care · biotechnology / orphan drugs · NASDAQ
Zevra Therapeutics is a rare-disease focused biotech company commercializing therapies for NPC and urea cycle disorders while advancing a late-stage pipeline.
What ZEVRA THERAPEUTICS INC does
Zevra Therapeutics is a commercial-stage biotechnology company focused on the development and commercialization of therapies for rare diseases. The company's portfolio includes approved treatments for Niemann-Pick disease type C (NPC) and urea cycle disorders, along with a pipeline of clinical-stage candidates targeting rare genetic conditions.
Recent developments
In July 2026, the company requested a re-examination of the CHMP's negative opinion regarding its European MAA for arimoclomol. The company also announced in March 2026 the divestiture of its SDX portfolio (including AZSTARYS and KP1077) to Commave Therapeutics to resolve pending litigation.
From ZEVRA THERAPEUTICS INC's filing of 2026-08-05.
Themes: rare disease, orphan drugs, neurological disorders, genetic disorders
Fundamentals
- Price$11.00 as of 2026-10-08 close
- Market cap$653M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+3.4% 2025-10-08 close $10.64 → 2026-10-08 close $11.00
- P/E11.35 as of 2026-10-08
- ROE+53.8% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)+119.4% as of 2026-09-02
- Beta0.73 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How ZVRA compares in its sector
- price-to-earnings ratiobottom 25% 185 covered Health Care peers, as of 2026-10-08
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ZEVRA THERAPEUTICS INC looks technically
ZEVRA THERAPEUTICS INC (ZVRA) is trading 4.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 110 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 5 trading days ago. It is 26.8% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 4.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +4.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.42 | $11.42 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.53 | $10.53 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 12.9. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 110 trading days ago — a "golden cross", a bullish long-term signal | 110 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 4.5% above | +4.5% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 16.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 46.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($9.85 to $11.88) — its "stochastic" reading is 57 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 56.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $15.04 | $15.04 |
|---|---|---|
| From the 52-week high | it is 26.8% below its 52-week high (its highest price of the past year) | -26.8% |
| Above the 52-week low | it is 37.3% above its 52-week low (its lowest price of the past year) | +37.3% |
| Below the 52-week high | it is 26.8% below its highest point of the past year | 26.8% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 49 trading days ago | 49 sessions |
| All-time high | its highest closing price on record is $418.40 (set on 2015-08-14) | $418.40 |
| Given back of the 52-week move | over the past year its closes ranged ($8.10 to $14.75), and it has given back around half of its rise from last year’s low — 56% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $10.43 to $10.64. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 56.4% |
| From the all-time high | it is 97.4% below its all-time high | -97.4% |
| Nearest price level | it is trading 2.3% above a support level at $10.75 — a price it turned at twice since 2025-07-28, most recently on 2026-08-14. Since 2024-10-08 it has 10 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.3% |
| All-time low | its lowest closing price on record is $1.94 (set on 2020-05-21) | $1.94 |
| Above the all-time low | it is 468.2% above its all-time low | +468.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 40th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4754 between its high and its low — about 4.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4754 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $10.16 and $12.35 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $10.16 – $11.26 – $12.35 |
| Typical daily range (% of price) | its price moves about 4.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is trading 1.0 daily range above its 200-day average price (4.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.0 daily range above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.51× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.3% |
|---|---|---|
| Gap filled | a 2.4% gap up opened on 2026-09-15 has been "filled" 17 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 17 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 14.3 percentage points (the stock lost 13.2% while the market gained 1.0%) | -14.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 29.3 percentage points (the stock lost 25.4% while the market gained 3.8%) | -29.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 4.5 percentage points (the stock gained 12.9% while the market gained 17.5%) | -4.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 11.6 percentage points (the stock gained 3.4% while the market gained 15.0%) | -11.6% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.7% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.9% of the share price. | -2.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.89 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +1.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $11.55 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | -4.8% |
Price levels it has turned at before
ZVRA last closed at $11.00 on 2026-10-08. Since 2024-10-08 it has turned at 10 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $10.75 | Support | 2.3% below the last close | turned there twice · 2025-07-28 to 2026-08-14 |
| $11.39 | Resistance | 3.6% above the last close | turned there twice · 2026-03-10 to 2026-08-31 |
| $9.98 | Support | 9.3% below the last close | turned there twice · 2025-11-18 to 2026-05-22 |
| $12.13 | Resistance | 10.3% above the last close | turned there four times · 2025-08-07 to 2026-08-20 |
| $9.58 | Support | 12.9% below the last close | turned there four times · 2025-06-11 to 2026-04-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $12.90.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 18 trading days, since 2026-09-15.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · trendless / choppy (low ADX) · Trading at this year’s average price paid (anchored VWAP) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.22 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$25.00 range $20.00 – $35.00; median $24.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ZVRA
- Consensus EPS estimate$0.1767 next reporting period, as of 2026-10-08
- Estimate change, 30 days-$0.00083 (-0.5%) from $0.1775, on 2026-09-02, 36-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the successful commercialization of MIPLYFFA and OLPRUVA and potential difficulties in establishing sales/distribution infrastructure.","Regulatory risks, including potential failure to obtain or maintain approvals for product candidates in the U.S. or international markets, such as the EMA re-examination process.","Fluctuating financial performance and reliance on future clinical trial outcomes for pipeline assets like celiprolol."]
What changed in the latest 10-Q
AI-assisted comparison of ZVRA's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K for fiscal year ended December 31, 2025, filed March 9, 2026 (vs. older filing referencing December 31, 2024, filed March 12, 2025)
- Newer filing states MIPLYFFA became commercially available in November 2024 in opening paragraph
- Newer filing adds statement that arimoclomol has been granted orphan medicinal product designation by European Commission
- Newer filing states MAA with EMA filed July 2025 and is currently under review
- Newer filing adds information about March 13, 2026 Commave Settlement Agreement to sell SDX portfolio assets including AZSTARYS and KP1077
- Newer filing reports net cash provided by operating activities of $6.1 million for three months ended March 31, 2026
- Newer filing updates product table to remove KP1077IH, KP1077N, and AZSTARYS as active development assets and status information
- Newer filing adds table header row with 'Status and IP' instead of 'Development Status' and 'Next Milestone(s)'
- Newer filing provides specific IP exclusivity dates in product table (ODE through 2031 for MIPLYFFA, IP through 2036 for OLPRUVA, IP potential through 2038 for Celiprolol)
- Removed:
- Older filing's language describing company as 'purpose-driven' with 'data-driven scientific approach and patient-first perspective' removed
- Older filing's statement about discontinuing in-house drug discovery and closing laboratory facilities in Iowa and Virginia removed
- Older filing's information about licensing IP related to prodrug of dextrorphan in April 2025 removed
- Older filing's reference to May 2022 purchase of Orphazyme assets and clawback liability removed
- Older filing's description of proprietary Ligand Activated Technology (LAT®) platform removed
- Older filing's entries for KP1077IH (Serdexmethylphenidate for Idiopathic Hypersomnia), KP1077N (Serdexmethylphenidate for Narcolepsy), and AZSTARYS (partnered product) removed from product table
- Older filing's reference to building diverse portfolio through internal development and strategic investments removed
- Reworded:
- Overview opening changed from 'purpose-driven, commercial-stage company focused on bringing life-changing therapeutics' to 'commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapeutics'
- Strategic plan description changed from 'five-year strategic plan focused on continued transformation' to 'strategic plan is focused on transforming Zevra into a leading rare-disease company'
- Language about pipeline expansion changed from 'both internal development and our business development activities to collaborate, partner, and potentially acquire' to 'through inorganic growth' and 'preferred partner for assets'
- Operating cash flow statement changed from nine months ended September 30, 2025 data to three months ended March 31, 2026 data
- NPC incidence statement added with specific patient population estimates (approximately 2,000 individuals in US and Europe combined, ~900 in US, ~1,100 in Europe)
- Notes:
- Text appears truncated at the end of newer filing, cutting off mid-sentence regarding NPC patient population
- Older filing text also appears truncated at the end, cutting off mid-sentence regarding anticipated milestones
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 2 sells ($613152) — 2 selling insiders
- Last 180 days · read to 2026-10-040 buys · 4 sells ($1M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-14. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ZVRA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ZVRA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 12,559,321
- Reported value $180,100,663
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ZVRA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ZVRA had 5,738,663 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ZVRA had 9.66% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.33 days to cover at the same settlement.
- Reported short interest (shares) 5,738,663
- Short interest (% of shares outstanding) 9.66%
- Prior settlement (shares) 5,771,206
- Reported change -0.56%
- Days to cover (reported) 6.33
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Travere Therapeutics (TVTX)
- Amicus Therapeutics (FOLD)
- Ultragenyx Pharmaceutical (RARE)
- BioMarin Pharmaceutical (BMRN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ZVRA vs…
ZEVRA THERAPEUTICS INC is found in…
ZVRA ranks in…
Frequently asked questions
What does ZEVRA THERAPEUTICS INC (ZVRA) do?
Zevra Therapeutics is a commercial-stage biotechnology company focused on the development and commercialization of therapies for rare diseases. The company's portfolio includes approved treatments for Niemann-Pick disease type C (NPC) and urea cycle disorders, along with a pipeline of clinical-stage candidates targeting rare genetic conditions.
What sector is ZEVRA THERAPEUTICS INC (ZVRA) in?
ZEVRA THERAPEUTICS INC (ZVRA) is classified in the Health Care sector. Its industry is biotechnology / orphan drugs. It trades on NASDAQ.
Who are ZEVRA THERAPEUTICS INC's (ZVRA) competitors?
Notable peers of ZEVRA THERAPEUTICS INC (ZVRA) include Travere Therapeutics, Amicus Therapeutics, Ultragenyx Pharmaceutical and BioMarin Pharmaceutical. This peer set is informational only — not financial advice.
Is ZEVRA THERAPEUTICS INC (ZVRA) overbought or oversold right now?
ZEVRA THERAPEUTICS INC (ZVRA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ZVRA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.